RYALTRIS (Seqirus Pty Ltd)
Product name
RYALTRIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
201 (255 working days)
Active ingredients
mometasone furoate monohydrate; olopatadine hydrochloride
Registration type
EOI
Indication
RYALTRIS (nasal spray) is now also indicated for the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 6 years of age and older.